不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
弥漫大 B 细胞淋巴瘤的医疗使用、成本与生存的真实世界模式：一项瑞典全国登记研究
英文原题：Real-world patterns of healthcare use, costs, and survival in diffuse large B-cell lymphoma: a nationwide Swedish register study.
查看英文原题
Real-world patterns of healthcare use, costs, and survival in diffuse large B-cell lymphoma: a nationwide Swedish register study.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
DLBCL 患者在专科诊疗中花费了大量时间，尤其是在诊断后的前两年。在此期间，医疗资源使用和费用保持稳定。本研究首次提供了瑞典 DLBCL 患者 HCRU 和直接费用的群体水平估计，为当前管理和未来整合不断演变的治疗策略提供了有价值的背景。
研究思路结论见上方概要
目的
描述瑞典DLBCL患者的医疗资源利用（HCRU）、直接成本和生存情况。
方法
这项回顾性队列研究利用瑞典国家登记数据库，对2015年至2023年的成人DLBCL患者进行了随访。专科诊疗时间以每人年（PPY）天数计算。采用北欧诊断相关组权重来估算费用。
结果
7,503 例患者被诊断为 DLBCL。中位年龄为 73.0 岁；56.9% 为男性，55.0% 有 1 种合并症。患者平均每年在护理中花费 17.6 天（每年 4.8%），平均费用为每年 15,417。HCRU 在第一年和第二年最高，分别为 41.7 天（11.4%）和 12.6 天（3.5%）在护理中。平均护理时间从 2015 年的 13.7 天（3.8%）下降到 2019 年的 11.9 天（3.3%），随后趋于稳定。自诊断起 1 年和 2 年的总生存率分别为 76.5%（95%CI：75.5-77.4）和 68.9%（95%CI：67.9-70.0）。
展开英文摘要原文
OBJECTIVES
To describe healthcare resource utilization (HCRU), direct costs, and survival of DLBCL patients in Sweden.
METHODS
This retrospective cohort study followed adult patients with DLBCL from 2015 to 2023 using Swedish national registers. Time in specialty care was calculated as days per-person-year (PPY). Nordic diagnosis-related-group weights were used to estimate costs.
RESULTS
7,503 patients were diagnosed with DLBCL. Median age was 73.0 years; 56.9% male and 55.0% had 1 comorbidity. On average, patients spent 17.6 days (4.8% annually) PPY in care, with average costs of 15,417 PPY. HCRU was highest in the first and second year with 41.7 days (11.4%) and 12.6 days (3.5%) in care, respectively. Average time in care declined from 13.7 days (3.8%) in 2015 to 11.9 days (3.3%) in 2019, then stabilized. Overall survival was 76.5% (95%CI: 75.5-77.4) and 68.9% (95%CI: 67.9-70.0) at 1 and 2 years from diagnosis.
CONCLUSIONS
DLBCL patients spent considerable time in specialist care, especially in the first two years post-diagnosis. Care use and costs remained stable over the period. This study provides the first population-level estimates of HCRU and direct costs for DLBCL in Sweden, offering valuable context for current management and future integration of evolving treatment strategies.
论文信息
- 作者
- Herweijer E、Miikkulainen K、Eklund O、Doble B、Holmberg C、Kanje VH、Thorén R、Jones CV
- 第一作者单位
- Ciencia Research AB, Drottninggatan 33, 111 51, Stockholm, Sweden.Sweden
- 通讯作者单位
- Ciencia Research AB, Drottninggatan 33, 111 51, Stockholm, Sweden. robyn.thoren@cienciaresearch.com.Sweden
- 期刊
- The European journal of health economics : HEPAC : health economics in prevention and care2026 Jul 13
- 原文标识
- PubMed 42440057 · DOI 10.1007/s10198-026-01964-x